Passer au contenu principal
Centre intégré universitaire de santé
et de services sociaux de l'Est-de-l'Île-de-Montréal

Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal

Isabelle Fleury, M.D., M. Sc.

Isabelle Fleury

Hémato-oncologue, Professeure agrégée de clinique

L'équipe de l’IHOT

Chercheur-clinicien

Contact

Tél. : 514 252-3404

Dre Isabelle Fleury a obtenu une maîtrise en sciences biomédicales de l’Université de Montréal en plus de sa formation médicale en hématologie-oncologie. Ses champs d’expertise sont les lymphomes et les thérapies à base de cellules immunes effectrices dont les CAR-T. 

 

  • Directrice du Programme CAR-T de HMR
  • Responsable médicale du Réseau québécois de thérapie immunocellulaire
  • Directrice du Programme de fellowship (DES) en lymphome et cellules immunes effectrices de l'Université de Montréal
  • Membre du Comité de priorisation clinique et recherche de l'IHOT
  • Membre du Comité d’optimisation clinique de l’IHOT
  • Entrée en poste à l’Hôpital Maisonneuve-Rosemont : 2014

 

Formation :

  • Fellowship en lymphome : Hôpitaux de Paris (AP-HP) et Hôpital Saint-Louis (France), 2013-2014
  • Résidences en médecine interne, hématologie et oncologie médicale : Université de Montréal (Canada), 2004-2011
  • Maîtrise en sciences biomédicales : Université de Montréal (Canada), 2001-2004
  • Doctorat en médecine : Université de Montréal (Canada), 2000-2004

Découvrez ses publications

  • A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma

    John Kuruvilla, Christopher Rushton, Diego Villa, Muhammad Aslam, Anca Prica, Nizar Abdel Samad, Stephane Doucet, Jill Dudebout , Isabelle Fleury , Graeme Fraser, Jean-Francois Larouche, Mona Shafey, Pamela Skrabek, Tanya Skamene, Ryan D. Morin, Miguel Alcaide, Susana Ben-Neriah, David Lee , Chad Winch, Lois E. Shepherd, David W. Scott, Michael Crump, Bingshu E. Chen, Annette E. Hay
    DOI 10.1111/bjh.19764 PMID 39267295
    Consulter

  • Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

    Franck Morschhauser, Saurabh Dahiya, M Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu , Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann , Isabelle Fleury , Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
    DOI 10.1038/s41591-024-03175-4 PMID 38982297
    Consulter

  • Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

    Franck Morschhauser, Saurabh Dahiya, M. Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto , Anna Maria Barbui, Jeremy S. Abramson, Peter Borchmann , Isabelle Fleury , Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J. Nastoupil
    DOI 10.1038/s41591-024-02986-9 PMID 38830991
    Consulter

  • Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisp

    Douglas A. Stewart, John Kuruvilla, David Lee, Jill J. Dudebout, Neil Chua, Jean-François Larouche, Tara Baetz, Mona Shafey, Nizar Abdel-Samad, Sue Robinson , Isabelle Fleury , Graeme Fraser, Pamela Skrabek, Vishal Kukreti, Jesse Kelly, Annette E. Hay, Lois E. Shepherd, Bingshu E. Chen, Michael Crump
    DOI 10.1111/bjh.19555 PMID 38802107
    Consulter

  • Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma

    Isabelle Fleury , Eva Laverdure
    DOI 10.58931/cht.2023.2338
    Consulter

  • Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

    Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan, Chaitra Ujjani, Nnadozie Emechebe, Rajesh Kamalakar, Catherine C Coombs , Lori Leslie 7, Paul M Barr 8, Jennifer R Brown, Toby A Eyre, Alexandros Rampotas, Anna Schuh, Nicole Lamanna, Alan Skarbnik, Lindsey E Roeker, Rajat Bannerji, Barbara Eichhorst , Isabelle Fleury , Matthew S Davids, Hasan Alhasani, Dingfeng Jiang, Brian T Hill, Stephen J Schuster , Danielle M Brander, Irina Pivneva, Rebecca Burne, Annie Guerin, Anthony R Mato
    DOI 10.1016/j.clml.2023.03.010 PMID 37076367
    Consulter

  • Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

    Jason R Westin, Olalekan O Oluwole, Marie José Kersten, David B Miklos, Miguel-Angel Perales, Armin Ghobadi, Aaron P Rapoport, Anna Sureda, Caron A Jacobson , Umar Farooq, Tom van Meerten, Matthew Ulrickson, Mahmoud Elsawy, Lori A Leslie, Sridhar Chaganti, Michael Dickinson, Kathleen Dorritie, Patrick M Reagan, Joseph McGuirk , Kevin W Song, Peter A Riedell, Monique C Minnema, Yin Yang, Saran Vardhanabhuti, Simone Filosto, Paul Cheng, Shilpa A Shahani, Marco Schupp, Christina To, Frederick L Locke; ZUMA-7 Investigators; Kite Members , Isabelle Fleury
    DOI 37272527 PMID 10.1056/NEJMoa2301665
    Consulter

  • Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refrac...

    Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters , Isabelle Fleury , Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles
    DOI 10.1007/s00277-023-05321-3 PMID 37432417
    Consulter

  • Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results

    Ulrich Jaeger, Nina Worel, Joseph P. McGuirk, Peter A. Riedell , Isabelle Fleury , Yan Du, Xia Han, David Pearson, Santiago Redondo, Edmund K. Waller
    DOI 10.1182/bloodadvances.2022007779 PMID 36044388
    Consulter

  • RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse ...

    Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters , Isabelle Fleury , Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia , Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles
    DOI 10.1007/s00277-023-05196-4 PMID 37171597
    Consulter

  • Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada

    Jean Lachaine, Kimberly Guinan, Andrew Aw, Versha Banerji , Isabelle Fleury , Carolyn Owen
    DOI 10.3390/curroncol30050339 PMID 37232797
    Consulter

  • Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge

    Sylvie Lachance , Alex Bourguignon, Josie-Anne Boisjoly, Philippe Bouchard , Imran Ahmad , Nadia Bambace , Léa Bernard , Sandra Cohen , Jean-Sébastien Delisle , Isabelle Fleury , Thomas Kiss , Luigina Mollica , Denis-Claude Roy , Guy Sauvageau , Olivier Veilleux , Justine Zehr, Miguel Chagnon , Jean Roy
    DOI 10.1016/j.jtct.2022.10.003 PMID 36243319
    Consulter

  • Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

    Grzegorz S. Nowakowski, Dok Hyun Yoon, Anthea Peters,Patrizia Mondello, Erel Joffe , Isabelle Fleury , Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotma, Dan Huang, Eva E Waltl, Mark Winderlich, Nuwan C Kurukulasuriya, Sumeet Ambarkhane, Georg Hess, Gilles Salles
    DOI 10.1158/1078-0432.CCR-21-3648 PMID 35674661
    Consulter

  • Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

    Ulrich Jaeger, Constantine S. Tam, Peter Borchmann, Joseph P. McGuirk, Marianne Johansen, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R. Foley, Jason R. Westin , Isabelle Fleury , P. Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J. Schuster, Fiona He, Richard T. Maziarz, Sebastian Mayer, Shinichi Makita, Marie J. Kersten, Monalisa Ghosh, Nina Wagner-Johnston , Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti-Bodoni, Michael R. Bishop
    DOI 10.1182/bloodadvances.2021006193 PMID 35687492
    Consulter

  • Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective

    Olivier Veilleux , Jean-Sébastien Claveau , Habiba Alaoui , Jean Roy , Imran Ahmad , Jean-Sébastien Delisle , Thomas Kiss , Nadia M Bambace , Léa Bernard , Sandra Cohen , Guy Sauvageau , Isabelle Fleury , Luigina Mollica , Denis-Claude Roy , Yasmina Serroukh , Sylvie Lachance
    DOI 10.1016/j.jtct.2021.12.005 PMID 34954149
    Consulter

  • Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

    Frederick L Locke, David B Miklos, Caron A Jacobson, Miguel-Angel Perales, Marie-José Kersten, Olalekan O Oluwole, Armin Ghobadi, Aaron P Rapoport , Joseph McGuirk, John M Pagel, Javier Muñoz, Umar Farooq, Tom van Meerten, Patrick M Reagan, Anna Sureda, Ian W Flinn, Peter Vandenberghe, Kevin W Song , Michael Dickinson, Monique C Minnema, Peter A Riedell, Lori A Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Jina Shah, Marco Schupp, Christina To, Paul Cheng, Leo I Gordon, Jason R Westin , Isabelle Fleury , All ZUMA-7 Investigators and Contributing Kite Members
    DOI 10.1056/NEJMoa2116133 PMID 34891224
    Consulter

  • Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

    Stephen J Schuster, Constantine S Tam, Peter Borchmann, Nina Worel, Joseph P McGuirk, Harald Holte, Edmund K Waller, Samantha Jaglowski, Michael R Bishop, Lloyd E Damon, Stephen Ronan Foley, Jason R Westin , Isabelle Fleury , P Joy Ho, Stephan Mielke, Takanori Teshima, Murali Janakiram, Jing-Mei Hsu, Koji Izutsu, Marie José Kersten, Monalisa Ghosh, Nina Wagner-Johnston, Koji Kato, Paolo Corradini , Marcela Martinez-Prieto, Xia Han, Ranjan Tiwari, Gilles Salles, Richard T Maziarz
    DOI 10.1016/S1470-2045(21)00375-2 PMID 34516954
    Consulter

  • Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada

    Jean Lachaine, Catherine Beauchemin, Kimberly Guinan, Philippe Thebault, Andrew Aw, Versha Banerji , Isabelle Fleury , Carolyn Owen
    DOI 10.3390/curroncol28010037 PMID 33435341
    Consulter

  • Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

    Pier Luigi Zinzani, Ian W. Flinn, Sam L. S. Yuen, Max S. Topp, Chiara Rusconi , Isabelle Fleury , Katell Le Dû, Christopher Arthur, Barbara Pro, Giuseppe Gritti, Michael Crump, Adam Petrich, Divya Samineni, Arijit Sinha, Elizabeth A. Punnoose, Edith Szafer-Glusman, Nathalie Spielewoy , Mehrdad Mobasher, Kathryn Humphrey, Martin Kornacker, Wolfgang Hiddemann
    DOI 10.1182/blood.2020005588 PMID 32785666
    Consulter

  • Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy

    Jiajia Liu, Douglas Stewart, Amelie Fontaine, Anthea Peters , Isabelle Fleury , Luigina Mollica , Anca Prica, Rena Buckstein, Laurie Sehn, Aixiang Jiang, John Kuruvilla, Diego Villa
    DOI 10.1080/10428194.2020.1772472 PMID 32519592
    Consulter

  • Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

    Richard T. Maziarz, Edmund K. Waller, Ulrich Jaeger , Isabelle Fleury , Joseph McGuirk, Harald Holte, Samantha Jaglowski, Stephen J. Schuster, Michael R. Bishop, Jason R. Westin, Stephan Mielke, Takanori Teshima, Veronika Bachanova, Stephen R. Foley, Peter Borchmann , Gilles A. Salles, Jie Zhang, Ranjan Tiwari, Lida B. Pacaud, Qiufei Ma, Constantine S. Tam
    DOI 10.1182/bloodadvances.2019001026 PMID 32074277
    Consulter

  • Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma

    Christopher Lemieux , Imran Ahmad , Nadia M. Bambace , Léa Bernard , Sandra Cohen , Jean-Sébastien Delisle , Isabelle Fleury , Thomas Kiss , Luigina Mollica , Denis-Claude Roy , Guy Sauvageau , Jean Roy , Sylvie Lachance
    DOI 10.1016/j.bbmt.2019.09.007 PMID 31521818
    Consulter

  • Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

    Michael R. Bishop, Richard T. Maziarz, Edmund K. Waller, Ulrich Jäger, Jason R. Westin, Joseph P. McGuirk , Isabelle Fleury , Harald Holte, Peter Borchmann, Christopher del Corral, Ranjan Tiwari, Özlem Anak, Rakesh Awasthi, Lida Pacaud, Vadim V. Romanov, Stephen J. Schuster
    DOI 10.1182/bloodadvances.2019000151 PMID 31332046
    Consulter

  • Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease

    Christopher Lemieux , Imran Ahmad , Nadia M. Bambace , Léa Bernard , Sandra Cohen , Jean-Sébastien Delisle , Isabelle Fleury , Thomas Kiss , Luigina Mollica , Denis-Claude Roy , Guy Sauvageau , Jean Roy , Sylvie Lachance
    DOI 10.1016/j.leukres.2019.01.002 PMID 30654975
    Consulter

  • Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin , Isabelle Fleury , Veronika Bachanova, S Ronan Foley, P Joy Ho, Stephan Mielke, John M Magenau, Harald Holte , Serafino Pantano, Lida B Pacaud, Rakesh Awasthi, Jufen Chu, Özlem Anak, Gilles Salles, Richard T Maziarz; JULIET Investigators
    DOI 10.1056/NEJMoa1804980 PMID 30501490
    Consulter

  • Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports

    Vanessa Brunet, Sofia Marouan, Jean-Pierre Routy, Mohamed Amin Hashem, Vincent Bernier, Raynald Simard, Tony Petrella, Louis Lamarre, Gilles Théorêt, Christian Carrier, Hans Knecht , Isabelle Fleury , Michel Pavic
    DOI 10.1097/MD.0000000000005985 PMID 28151891
    Consulter

  • Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment

    Sandy Amorim , Isabelle Fleury , Nicolas Mounier, Stéphanie Harel, Pauline Brice, Catherine Thieblemont
    DOI 10.3109/10428194.2015.1135437 PMID 26750643
    Consulter

  • Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis

    Isabelle Fleury , S Chevret, M Pfreundschuh, G Salles, B Coiffier, M H J van Oers, C Gisselbrecht, E Zucca, M Herold, M Ghielmini, C Thieblemont
    DOI 10.1093/annonc/mdv616 PMID 26681685
    Consulter

  • Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study

    Isabelle Fleury , Sandy Amorim, Nicolas Mounier, Bertrand Coiffier, Jehan Dupuis, Hervè Tilly, Mohamed A Mazari, Lauriane Filliatre, Josette Brière, Pauline Brice, Eric de Kerviler, Catherine Thieblemont
    DOI 10.3109/10428194.2014.977884 PMID 25347431
    Consulter

  • No association between telomere length and blood cell counts in elderly individuals

    Luigina Mollica , Isabelle Fleury , Claude Belisle, Sylvie Provost , Denis-Claude Roy , Lambert Busque
    DOI 10.1093/gerona/glp065 PMID 19435952
    Consulter

  • Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia

    Isabelle Fleury , Melanie Primeau, Agnes Doreau, Irina Costea, Albert Moghrabi, Daniel Sinnett, Maja Krajinovic
    DOI 10.2165/00129785-200404050-00006 PMID 15462611
    Consulter

  • Characterization of the BclI polymorphism in the glucocorticoid receptor gene

    Isabelle Fleury , Patrick Beaulieu, Melanie Primeau, Damian Labuda, Daniel Sinnett, Maja Krajinovic
    DOI 10.1373/49.9.1528 PMID 12928238
    Consulter